Arutimol drops Ch. 0.25% 5ml fl.p / e

Description

Composition
Active substance:
1 ml of solution contains: timolol maleate – 3.42 mg (equivalent to Timolol 2.50 mg) or timolol maleate – 6.83 mg (corresponding to 5.0 mg of timolol).
Excipients:
Benzalkonium chloride solution (50%) corresponds to benzalkonium chloride, povidone K 30, sodium dihydrogen phosphate dihydrate, sodium monohydrogen phosphate dodecahydrate, disodium edetate dihydrate, water for injection.
Description:
The clear solution, colorless or yellowish white, odorless.
Product form:
Eye drops of 2.5 mg / ml and 5 mg / ml.
5 ml vial of low density polyethylene, a sealed screw cap with an opening of the needle polypropylene. On the bottle label paste. The vial together with instructions for use placed in a cardboard box.
Contraindications
Bronchial asthma, or other severe chronic obstructive airway disease; sinus bradycardia; cardiogenic shock; atrioventricular block II – III degree; heart failure; degenerative processes in the cornea; heavy atrophic rhinitis; allergic reactions to components of the drug; pregnancy and lactation; Children up to age 18 years.
Carefully.
In patients with pulmonary insufficiency, severe cerebrovascular insufficiency, congestive heart failure, diabetes, hypoglycemia, hyperthyroidism, myasthenia, Raynaud’s syndrome, pheochromocytoma, and with concomitant administration of other beta-blockers. In patients with diabetes, insulin or oral hypoglycemic agents, timolol may lead to hypoglycemia.
Dosage
0.25%
Indications
Elevated intraocular pressure (ocular hypertension); open-angle glaucoma; afakicheskaya glaucoma and other forms of secondary glaucoma; as an additional means for reducing the intraocular pressure in angle-closure glaucoma (in combination with miotikami); congenital glaucoma (with other therapeutic measures failure).
Interaction with other drugs
Sharing with timolol eye drops containing epinephrine may cause pupil dilation.
The specific effect of the drug – reduction of intraocular pressure is enhanced by the simultaneous use of eye drops containing pilocarpine and epinephrine; instilled into the eyes of two beta-blockers should not be. lowering blood pressure and slowing down heart rate can potentiate the joint application of the drug with calcium antagonists, reserpine and beta-blockers.
Concomitant use with insulin or oral hypoglycemic agents can cause hypoglycemia.
Timolol increases the effects of muscle relaxants, so the necessary removal of the drug 48 hours before planned surgery with general anesthesia.
These data may also apply to drugs that have been used shortly before.
Overdose
May develop systemic effects typical of beta-blockers: dizziness, headache, arrhythmia, bradycardia, decreased blood pressure, heart failure, bronchospasm, nausea, and vomiting.
Treatment: rinse immediately with water or 0.9% sodium chloride solution, symptomatic therapy.
pharmachologic effect
Pharmacological group:
Antiglaucoma agents – beta-blocker.
Pharmacodynamics:
Timolol is a non-selective blocker of beta-1 and beta-2 adrenergic receptors. It has no intrinsic sympathomimetic and membrane stabilizing activity.
When applied topically as eyedrops reduce both normal and elevated intraocular pressure by decreasing the formation of intraocular fluid. It has no effect on pupil size and accommodation. The action of the drug is 20 minutes after instillation into conjunctival cavity. The maximum decrease in IOP occurs within 1-2 hours and lasts for 24 hours.
Pharmacokinetics:
When applied topically, timolol rapidly penetrates through the cornea. After instillation of the eye drops the maximum concentration of timolol in the aqueous humor of the anterior chamber is reached after 1 to 2 hours. 80% timolol applied as eyedrops, enters the systemic circulation by absorption through the vessels of the conjunctiva, nasal mucosa and the lacrimal canal.
Timolol excretion of metabolites is done primarily by the kidneys.
In infants and young children the concentration of timolol as the active substance, substantially greater than the maximum concentration (Cmax) in the blood plasma of adults.
Conditions of supply of pharmacies
On prescription.
side effects
Local reactions: irritation and redness of the conjunctiva, eyelid skin, burning and itching in the eyes, tearing, photophobia, edema of the corneal epithelium, superficial punctate keratopathy, corneal hypoesthesia, diplopia, ptosis. In conducting fistuliziruyuschih antiglaukomatoznyh operations may develop choroidal detachment in the postoperative period.
Systemic reactions:
Cardio-vascular system: congestive heart failure, bradycardia, bradyarrhythmia, decreased blood pressure, collapse, atrioventricular block, cardiac arrest, heart palpitations, hypoperfusion of the brain, and transient ischemic attacks.
The respiratory system: rhinitis, dyspnea, bronchospasm, pulmonary insufficiency.
Central nervous system: headache, dizziness, weakness, depression, paresthesia.
On the part of the gastrointestinal tract: nausea, diarrhea.
Allergic reactions: urticaria, eczema.
Urogenital system: sexual dysfunction.
Skin: alopecia.
In the case of side effects, discontinue use of the drug and how to contact your doctor as soon as possible (ophthalmologist).
special instructions
You need to see your doctor regularly to measure intraocular pressure and corneal examination.
If the patient wears contact lenses are soft, then it should not apply the eyedrops Arutimol 2.5 mg / ml and 5 mg / ml, since it contains a preservative that can be adsorbed soft contact lenses and have adverse effects on eye tissues.
Immediately after instillation of possible short-term decrease in visual acuity.
It is hard to remove contact lenses before instillation of the preparation and putting them again only 15 minutes after instillation.
During treatment, care must be taken when driving and other lesson. Potentially hazardous activities that require high concentration, psychomotor speed of reaction and a good vision (for 30 minutes after instillation into the eye) because the drug can reduce the blood pressure, the appearance fatigue and dizziness. In an even greater extent this occurs in the interaction of the drug with alcohol.
When transferring patients to treatment with eye drops Arutimol 2.5 mg / ml and 5 mg / ml may be required refractive correction after effects caused by the previously used miotikami.
In the case of the upcoming surgery using general anesthesia is necessary to stop the drug for 48 hours.
Storage conditions
Store in a dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
At the beginning of therapy instilled 1 drop preparation Arutimol 2.5 mg / mL or 5 mg / ml in the conjunctival sac 2 times per day.
When intraocular pressure normalization maintenance dose – 1 drop of 2.5 mg / ml 1 time per day.
Arutimolom Treatment 2.5 mg / mL or 5 mg / ml is carried out, usually for a prolonged time. Suspension or change the dosage are carried out only by order of a physician.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist